Have Incannex Healthcare shares been a good investment in 2022?

We check what's been happening with the ASX cannabis share lately.

| More on:
two men in formal business clothing closely inspect a bud from a cannabis crop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Incannex share price has taken a battering, losing half its value in 2022 so far
  • The ASX cannabis share is now included in the ASX 300 
  • In FY22, Incannex recorded a net loss of almost $15 million

The Incannex Healthcare Ltd (ASX: IHL) share price has had a tough 2022, losing 50% of its value year to date.

That's far lower than the S&P/ASX 200 Health Care Index (ASX: XHJ), which is down 5.24% for the same period.

However, Incannex is not alone among ASX cannabis shares. Emyria Ltd (ASX: EMD) has shed 42% while Creso Pharma Ltd (ASX: CPH) is down more than 60% so far this year.

Let's make sense of what may have impacted Incannex's performance lately

What's going on with Incannex Healthcare?

The company is now included in the S&P/ASX 300 Index (ASX: XKO) as part of S&P Global's quarterly rebalancing that took place at the beginning of the month.

In August, Incannex also completed its acquisition of APRIx Pharmaceuticals for US$93.3 million after the companies reached an agreement in March this year.

When the deal went through, Incannex claimed it now held "the world's largest portfolio of patented medicinal cannabinoid drug formulations and psychedelic treatment protocols".

Earlier in August, Incannex released an investor presentation giving an overview of its operations and other aspects of the business.

At that time, it noted it had an estimated $290 billion total addressable market for its lead drug candidates and another $2 billion per year in potential revenue from psychedelic treatment therapies.

And finally, the company posted its results for FY22, noting that its net loss from ordinary activities increased 31% to $14.9 million from the prior reporting period while also recording no revenues.

Icannex share price snapshot

The Icannex share price finished 6.78% higher today at 31.5 cents, a long way from its 52-week closing high of 73 cents in early March.

The company's current market capitalisation is around $479 million.

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Healthcare Shares

How big could the return be with CSL shares in 2024?

Could this biotech company be a market beater in 2024?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Here's why I can't wait to buy Chemist Warehouse shares

Chemist Warehouse would ticks all of my boxes for a great investment.

Read more »

Five arrows hit the bullseye of five round targets lined up in a row, with a blue sky in the background.
Healthcare Shares

When might CSL shares hit the $300-mark again?

CSL is on track for $300, if one broker is to be believed.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

2 ASX healthcare shares I think are overdue for a big rally

I think these early stage drug companies could have a barnstorming 2024.

Read more »

Businesswoman whispering in male colleague's ear as he looks surprised
Share Gainers

Up 118%: Is this 'high quality' stock the best-kept secret on the ASX 200?

Why are these pharmaceutical shares turning heads at the moment? The Elvest team explains.

Read more »

a woman puts a pen to her mouth as she smiles slightly while checking an old book style diary/calendar.
Healthcare Shares

Dates that could move the NIB share price in 2024

NIB shares investors, get out your 2024 diaries...

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

ASX 300 healthcare stock Sigma halted amid rumours of blockbuster Chemist Warehouse deal

Is Chemist Warehouse finally joining the ASX?

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

Guess which ASX 200 healthcare stock is surging 8% on record sales

This medical device company's sales growth was strong in November.

Read more »